ADCs
| Antibody . | Target . | Drug . | Indication . | Stage of development . |
|---|---|---|---|---|
| BV | CD30 | Monomethyl auristatin E | HL, ALCL | Approved 2011 |
| BT062 | CD138 | DM4 (Maytansinoid) | MM | Phase 2 NCT01001442, NCT01638936 |
| Polatuzumab vedotin (DCDS4501A) | CD79b | Monomethyl auristatin E | DLBCL, FL | Phase 2 NCT01691898 |
| GO | CD33 | Calicheamicin | AML | Approved 2000; withdrawn June 2010 |
| INO (CMC-544) | CD22 | Calicheamicin | B-cell NHL, B-cell ALL | Phase 3 NCT01564784, NCT01232556 |
| IMGN529 | CD37 | DM1 (Maytansinoid) | B-cell NHL, B-cell CLL | Phase 1 NCT01534715 |
| Milatuzumab-doxorubicin (hLL1-Dox; IMMU-110) | CD74 | Doxorubicin | MM, CLL, NHL | Phase 1/2 NCT01101594 |
| PV (DCDT2980S) | CD22 | Monomethyl auristatin E | DLBCL, FL | Phase 2 NCT01691898 |
| SAR-3419 | CD19 | DM4 (Maytansinoid) | DLBCL, B-cell ALL | Phase 2 NCT01472887, NCT01440179 |
| SGN-CD19A | CD19 | Monomethyl auristatin F | B-cell NHL, B-cell ALL | Phase 1 NCT01786135, NCT01786096 |
| SGN-CD33A | CD33 | Pyrrolobenzodiazepine dimer | AML | Phase 1 NCT01902329 |
| Antibody . | Target . | Drug . | Indication . | Stage of development . |
|---|---|---|---|---|
| BV | CD30 | Monomethyl auristatin E | HL, ALCL | Approved 2011 |
| BT062 | CD138 | DM4 (Maytansinoid) | MM | Phase 2 NCT01001442, NCT01638936 |
| Polatuzumab vedotin (DCDS4501A) | CD79b | Monomethyl auristatin E | DLBCL, FL | Phase 2 NCT01691898 |
| GO | CD33 | Calicheamicin | AML | Approved 2000; withdrawn June 2010 |
| INO (CMC-544) | CD22 | Calicheamicin | B-cell NHL, B-cell ALL | Phase 3 NCT01564784, NCT01232556 |
| IMGN529 | CD37 | DM1 (Maytansinoid) | B-cell NHL, B-cell CLL | Phase 1 NCT01534715 |
| Milatuzumab-doxorubicin (hLL1-Dox; IMMU-110) | CD74 | Doxorubicin | MM, CLL, NHL | Phase 1/2 NCT01101594 |
| PV (DCDT2980S) | CD22 | Monomethyl auristatin E | DLBCL, FL | Phase 2 NCT01691898 |
| SAR-3419 | CD19 | DM4 (Maytansinoid) | DLBCL, B-cell ALL | Phase 2 NCT01472887, NCT01440179 |
| SGN-CD19A | CD19 | Monomethyl auristatin F | B-cell NHL, B-cell ALL | Phase 1 NCT01786135, NCT01786096 |
| SGN-CD33A | CD33 | Pyrrolobenzodiazepine dimer | AML | Phase 1 NCT01902329 |
ALCL, anaplastic large cell lymphoma; CLL, chronic lymphocytic leukemia.